EcoDrugPlus

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSMICG00000004173
Gene Symbol: HTR2B
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSMICG00000032281
Gene Symbol: HTR2C
4 Cross references
225 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMICG00000010063
Gene Symbol: HTR3A
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSMICG00000010056
Gene Symbol: HTR3B
4 Cross references
174 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3c

Ensembl ID : ENSMICG00000049301
Gene Symbol: HTR3C
3 Cross references
57 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSMICG00000049068
Gene Symbol: HTR3E
4 Cross references
38 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSMICG00000002566
Gene Symbol: HTR4
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSMICG00000028832
Gene Symbol: HTR6
4 Cross references
114 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSMICG00000011996
Gene Symbol: HTR7
4 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L12 Pseudogene

Ensembl ID : ENSMICG00000017533
Gene Symbol: LOC105865945
2 Cross references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L15 Pseudogene

Ensembl ID : ENSMICG00000000112
Gene Symbol: LOC105871206
2 Cross references
142 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L21 Pseudogene

Ensembl ID : ENSMICG00000042687
Gene Symbol: LOC105872400
2 Cross references
138 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).